Review Explores Challenges of Ocular Antioxidants for Cataracts

This article originally appeared here.
Share this content:
Review Explores Challenges of Ocular Antioxidants for Cataracts
Review Explores Challenges of Ocular Antioxidants for Cataracts

FRIDAY, April 17, 2015 (HealthDay News) -- Delivery of antioxidants to the eye may be a therapeutic option for cataracts, but considerable challenges need to be resolved, according to a review published in the April issue of the Journal of Pharmacy and Pharmacology.

Hamdy Abdelkader, Ph.D., from Kingston University London, and colleagues discuss the role of antioxidants as a therapeutic option for cataracts.

The authors note that there are contradictory findings in the literature about the utility of oral antioxidant supplementation, with long-term supplementation considered to be of limited benefit. Current research is focusing on development of advanced delivery systems for better ocular bioavailability and consequently better therapeutic outcomes. Topical ocular drug delivery is the preferred route but many anatomic and physiological barriers form part of the natural defense of the eye. Nanotechnology offers the potential of formulations that are small enough to prevent blockage of the anterior chamber, have appropriate functionalities, and can possess inherent antioxidant function or can deliver antioxidants.

"However, as thus far, oral supplementation of antioxidants has not been effective given the difficulties in delivery to the lens," the authors write. "Future directions for therapeutic measures should concentrate on effective drug delivery modes that can pass through the outer coats of the eye and through the capsule of the lens without disrupting the fluid exchange mechanism in the anterior chamber."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »